title: [Latent tuberculosis treatment results in patients that taken TNF-alpha blockers at Ankara Numune Training and Research Hospital Chest Diseases Clinic for last 8 years (2006-2013)].
abstract: BACKGROUND
  Tuberculosis occurrence was evaluated in patients that applied tuberculosis chemoprophylaxis and currently receiving tumor necrosis factor-alpha (TNF-α) blocker.
  
  
  METHODS
  Incidence of tuberculosis were retrospectively evaluated in patients that currently receiving TNF-α-blocking therapy and received tuberculosis chemoprophylaxis at Ankara Numune Education and Research Hospital, Lung Disease Department, between 2006-2013 years. 134 patients that were diagnosed with rheumatologic and dermatologic diseases, were evaluated. Patients were in the age range 18-80 years. Age, gender, smoking status, BCG vaccination, chest radiography, diagnose of disease, presence of concomitant disease, tuberculosis story, PPD value, chemoprophylaxis acquisition, which anti-tuberculosis agents received, duration of chemoprophylaxis, duration of TNF-α blocker, other immunosuppressive using were measured.
  
  
  RESULTS
  Rheumatologic diseases were often. Prophylaxis has given at 73.9% of patients. Patients with received anti-TNF-α therapy (n= 134) have not developed pulmonary or extra-pulmonary tuberculosis disease.
  
  
  CONCLUSIONS
  Patients with received anti-TNF-α therapy, are scanned with TST or Quantiferon. If latent tuberculosis infection are diagnosed, tuberculosis prophylaxis should be started pre-anti-TNF-α therapy at least one month and INH chemoprophylaxis should be completed on 9 months or RIF should be completed on 4 months. Serum liver enzymes and bilirubin measurements monthly; follow-up physical examination and chest radiography should be performed for 3 months.
authors.affiliation: Clinic of Chest Diseases, Ankara Numune Training and Research Hospital, Ankara, Turkey. drsemad@yahoo.com.
authors.forename: Sema
authors.initials: S
authors.lastname: Demir
authors.forename: Filiz
authors.initials: F
authors.lastname: Sadi Aykan
authors.forename: Derya
authors.initials: D
authors.lastname: Öztuna
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000995:Antitubercular Agents / Q000008:administration & dosage*; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage*; D015994:Incidence; D055985:Latent Tuberculosis / Q000188:drug therapy / Q000453:epidemiology*; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D014409:Tumor Necrosis Factor-alpha / Q000008:administration & dosage*; D014421:Turkey / Q000453:epidemiology
chemical_list: D000995:Antitubercular Agents; D007166:Immunosuppressive Agents; D014409:Tumor Necrosis Factor-alpha